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Parkinson’s disease (PD) symptoms have been collectively ascribed to malfunctioning of
dopamine-related nigro-striatal and cortico-striatal loops. However, some doubts about this
proposition are raised by controversies about the temporal progression of the impairments,
and whether they are concomitant or not. The present study consists of a systematic revi-
sion of literature data on both functional PD impairments and dopaminergic medication
effects in order to draw a coherent picture about the disease progression. It was done in
terms of an explanatory model for the disruption of implicit knowledge acquisition, motor
and cognitive impairments, and the effects of dopaminergic medication on these func-
tions. Cognitive impairments arise at early stages of PD and stabilizes while disruption of
implicit knowledge acquisition and motor impairments, are still in progression; additionally,
dopaminergic medication reduces motor impairments and increases disruption of implicit
knowledge acquisition. Since this model revealed consistency and plausibility when con-
fronted with data of others studies not included in model’s formulation, it may turn out to
be a useful tool for understanding the multifaceted characteristics of PD.
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INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative con-
dition that has typically been considered to be a motor disorder
associated to basal ganglia dysfunction (Marsden, 1982). The main
features of PD (i.e., akinesia or bradykinesia, rigidity, and tremor)
are mainly related to dysfunction of the motor circuit, involv-
ing basal ganglia, thalamus, and motor cortex (Rodriguez-Oroz
et al., 2009). Additionally to motricity, the basal ganglia networks
are now known to be anatomically and physiologically associ-
ated to learning and working memory (Sawamoto et al., 2008;
Marklund et al., 2009). The association of motor (performance of
skilled movements), implicit learning (degree of improvement by
repetitive performance of a task, without declarative knowledge
about the reasons for this improvement) and cognitive symptoms
(dependent of working memory and attention) along progression
of PD are a matter of debate.
Muslimovic et al. (2007) proposed that cognitive impair-
ments are independent of disruption of implicit knowledge
acquisition. Similarly, Cooper et al. (1991) reported weak cor-
relations between cognitive and motor symptoms in patients
at early stages of PD tested under no effects of dopaminer-
gic medication. On the other hand, Fama and Sullivan (2002)
showed strong correlations between motor impairments and
disruption of implicit knowledge acquisition in patients tested
under effect of dopaminergic medication, and Vandenbossche
et al. (2009) reported correlations between motor and cogni-
tive impairments in patients scored at the same Hoehn and Yahr
(1967) stages, when tested under effect of dopaminergic med-
ication. Additionally, Pavão et al. (unpublished) showed posi-
tive correlation between motor, implicit acquisition, and motor
impairments in patients tested under no effect of dopaminergic
medication.
These seemingly inconsistent findings may be ascribed to non-
linear relationships among these impairments, and that these func-
tions are differently influenced by dopaminergic medication. For
formalizing this conception, we propose a single unifying model
for explaining the progression of PD, supported by literature data
relative to patients and healthy volunteers tested both with and
without the effects of dopaminergic medication.
THE PROPOSAL OF A UNIFYING MODEL
Assuming that the impairments in PD progress in three major
domains, including motor performance, implicit knowledge
acquisition, and general cognitive changes, and that each of these
domains suffer distinct influences of dopaminergic medication
administration, we analyzed findings of different studies report-
ing on the progression of these impairments in PD patients, as well
on the effects of dopaminergic medication on the performance of
healthy subjects submitted to these tests.
This analysis revealed major trends (see Table S1 in Supplemen-
tary Material) and provided information to propose a unifying
model aiming at explaining the relationships among these three
domains of disease progression, and how dopaminergic medica-
tion affects the corresponding test results [Figure 1 – numbers and
letters (identification codes) identify studies which lend support
to this model and also identify the references included in Table
S1 in Supplementary Material]. Although the model takes into
account interactions among all three domains, it is described by
analyzing the interactions between pairs of domains to facilitate
understanding.
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FIGURE 1 | Model showing the relationships between cognitive
impairments as a function of disruption of implicit knowledge acquisition
(general findings better adjusted to an arc-tangent function) (A), motor
impairment as a function of disruption of implicit knowledge acquisition
(general findings better adjusted to a linear function) (B), motor
impairment as a function of cognitive impairment (general findings
congruent with the other functions) (C), and an unified tri-dimensional
model expressing the interaction between motor impairment, disruption
of implicit knowledge acquisition, and cognitive impairment (D), in
healthy volunteers (represented by the lines corresponding to the “zero”
cognitive impairment, the “zero” disruption of acquisition of implicit
knowledge and the “zero” motor impairment, tested without
dopaminergic medication) and patients with PD tested with and without
dopaminergic medication effects along disease progression up to a
maximum (max) of disruption. The studies that lend support to this model
are indicated by identification codes (see below) and their results (i.e.,
differences, lack of differences, and correlations) are represented by gray lines
with their extreme points corresponding to compared samples. Identification
codes: Caviness et al. (2007) (1), Cools et al. (1984) (2a, 2b), Cooper et al.
(1991) (3a, 3b, 3c, 3d), Delaveau et al. (2005) (4), de Vries et al. (2010) (5), Fama
and Sullivan (2002) (6a, 6b, 6c), Floel et al. (2005) (7), Floel et al. (2008) (8),
Girotti et al. (1986) (9a, 9b, 9c, 9d), Growdon et al. (1998) (10a, 10b), Hasbroucq
et al. (2003) (11), Morrison et al. (2004) (12), Mortimer et al. (1982) (13),
Muslimovic et al. (2007) (14a, 14b, 14c, 14d, 14e, 14f, 14g, 14h), Pavão et al.
(unpublished) (15a, 15b, 15c), Sabbe et al. (2004) (16), Seo et al. (2010) (17a,
17b, 17c), Stocchi et al. (2005) (18), Vandenbossche et al. (2009) (19a, 19b, 19c),
Verbaan et al. (2007) (20a, 20b), Wilkinson and Jahanshahi (2007) (21a, 21b;
see Table S1 in Supplementary Material for a summary of the original data).
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DISRUPTION OF IMPLICIT KNOWLEDGE ACQUISITION AND COGNITIVE
IMPAIRMENTS
Figure 1A represents the increase in general cognitive impairments
as a function of disruption of implicit knowledge acquisition;
while a leftward shift of the curve represents better acquisition
of implicit knowledge, an upward shift indicates poorer cognitive
performance. This figure shows that there is a rapid initial increase
in cognitive impairment in PD when disruption of implicit knowl-
edge acquisition remains almost absent; as the disease further
progresses, this is followed by a much slower increase in cognitive
impairments associated with acceleration of the disruption of
implicit knowledge acquisition, assessed either with or without
dopaminergic medication effects. In addition, while dopaminergic
medication shifts the curve slightly leftwards and upwards in both
healthy volunteers and patients at early stages of PD, it extends the
curve rightwards in patients at advanced stages of PD.
These relationships are supported by data from different stud-
ies indicated by the identification codes shown in Figure 1 and
Table S1 in Supplementary Material. As seen above, Muslimovic
et al. (2007) showed that disruption of implicit knowledge acqui-
sition and cognitive impairments do not correlate with each other
along PD progression (Figure 1A, identification code 14a indicat-
ing lack of significant correlation for PD patients at advanced
stages). Differently, the study by Vandenbossche et al., 2009;
Figure 1A, identification code 19a) and Pavão et al. (unpub-
lished; identification code 15a) revealed consistent correlations
between performances of PD patients in tasks evaluating these
functions.
This apparent conflict seems to be related to the inclusion
of patients at different disease stages. The study by Muslimovic
et al. (2007) evaluated some PD patients at early disease stages but
mostly patients at advanced disease stages; in contrast, the studies
by Vandenbossche et al. (2009), Pavão et al. (unpublished), and
Mortimer et al. (1982) included patients varying from early to
advanced stages (see Table S1 in Supplementary Material).
As indicated in Figure 1A, at early stages of PD cognitive
impairments are associated with relatively preserved implicit
knowledge acquisition. Cooper et al. (1991) and Muslimovic
et al. (2007) data lend support to this conclusion: the identifica-
tion codes 3c and 14c (see Table S1 in Supplementary Material;
Figure 1A), shows significant cognitive impairments by non-
medicated PD patients at early stages of the disease compared to
healthy subjects (represented in Figure 1 as “zero” impairments);
identification code 14f (see Table S1 in Supplementary Material;
Figure 1A) shows lack of significant disruption of implicit knowl-
edge acquisition by non-medicated PD patients at early stages of
the disease relative to healthy subjects).
At advanced stages of PD cognitive impairments have already
reached a plateau, which is not changed by dopaminergic med-
ication (Figure 1A, identification codes 9b and 12; Girotti et al.,
1986; Morrison et al., 2004; see Table S1 in Supplementary Mate-
rial) while disruption of implicit knowledge acquisition is still
progressing; thus, assessments involving only patients at extreme
stages of PD should reveal no correlations (Figure 1A, 14a; Mus-
limovic et al., 2007) associated with substantial disruption relative
to healthy subjects both in cognitive (Figure 1A, identification
codes 2a, 6b, 9a, 14b, and 20b; Cools et al., 1984; Girotti et al.,
1986; Fama and Sullivan, 2002; Muslimovic et al., 2007; Verbaan
et al., 2007), and implicit knowledge acquisition tasks (Figure 1A,
identification codes 2b, 14e, 17a, 17b, and 21a; Cools et al., 1984;
Muslimovic et al., 2007; Wilkinson and Jahanshahi, 2007; Seo
et al., 2010). In contrast, as seen above, assessments of patients
at diverse disease stages, like those participating in Pavão et al.
(unpublished) and Vandenbossche et al. (2009), revealed signif-
icant correlations between these two impairments (Figure 1A,
identification codes 15a and 19a).
The model also takes into account that healthy volunteers sub-
jected to dopaminergic medication exhibit small but significant
cognitive impairments (Sabbe et al., 2004; Delaveau et al., 2005;
Figure 1A, identification codes 4 and 16) and small but signifi-
cant improvements in implicit knowledge acquisition (Floel et al.,
2005; de Vries et al., 2010; Figure 1A, identification codes 5 and 7;
see Table S1 in Supplementary Material).
In contrast, PD patients tested without the effects of dopamin-
ergic medication do not exhibit changes in cognitive function
when compared to PD patients tested under dopaminergic med-
ication effects (Girotti et al., 1986; Growdon et al., 1998; Morrison
et al., 2004; Figure 1A, 9b, 10a, and 12). In addition, PD patients
at advanced stages of the disease tested without the effects of
dopaminergic medication exhibit small but significant disruption
of implicit knowledge acquisition relative to patients at corre-
sponding stages tested under dopaminergic medication effects
(Seo et al., 2010; Figure 1A, identification code 17c; see Table
S1 in Supplementary Material).
DISRUPTION IN ACQUISITION OF KNOWLEDGE IMPLICIT AND MOTOR
IMPAIRMENT
The relationship between disruption of implicit knowledge
acquisition and motor impairment was assumed to be linear
(Figure 1B), thus capturing evidence of positive correlations
between these functions (Muslimovic et al., 2007; Vandenboss-
che et al., 2009; Pavão et al., unpublished). The model represents
the well-known benefit of dopaminergic medication reducing
motor impairments (e.g., Girotti et al., 1986; Growdon et al., 1998;
Stocchi et al., 2005; Figure 1B, identification codes 9d, 10b, and
18; see Table S1 in Supplementary Material) and dopaminergic
medication-induced worsening of disruption of implicit knowl-
edge acquisition (e.g., Seo et al., 2010; Figure 1B, 17c). In addition,
the model also incorporates evidence that healthy volunteers sub-
jected to dopaminergic medication exhibit improvement in both
motor (Hasbroucq et al., 2003; Floel et al., 2008; Figure 1B, 8 and
11) and implicit knowledge acquisition (Floel et al., 2005; de Vries
et al., 2010; Figure 1B, 5 and 7).
The motor and implicit knowledge acquisition functions are
thought to be closely related in PD. Muslimovic et al. (2007)
reported significant correlations of performance in tasks eval-
uating disruption in implicit knowledge acquisition and motor
impairments (Figure 1B, 14d). Cooper et al. (1991) showed that
patients at early stages of PD tested without the effects of dopamin-
ergic medication exhibited poorer performance in a motor task
when compared to healthy subjects in a finger movement test
(Figure 1B, 3d).
A different effect was reported by Muslimovic et al. (2007)
for patients at early stages of PD tested without the effects of
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dopaminergic medication both in a motor (Figure 1B, 14h) and
implicit knowledge acquisition tasks (Figure 1B, 14f). However,
when these authors included data from patients at advanced stages
of PD tested with the effects of dopaminergic medication, the
whole group exhibited poorer motor performance and implicit
knowledge acquisition when compared to healthy volunteers
(Figure 1B, 14g and 14e).
Similar findings either with or without dopaminergic med-
ication were reported by Cools et al. (1984), Seo et al. (2010),
and Wilkinson and Jahanshahi (2007), relative to implicit knowl-
edge acquisition (Figure 1B, 2b, 17a, 17b, and 21a), and by
Fama and Sullivan (2002), Girotti et al. (1986), and Wilkinson
and Jahanshahi (2007), relative to motor performance in patients
receiving dopaminergic medication compared to healthy subjects
(Figure 1B, identification codes 6c, 9c, and 21b).
Correlations between disruption of implicit knowledge acqui-
sition and motor impairments by patients at different stages of
disease were reported by Vandenbossche et al. (2009) on patients
receiving dopaminergic medication (Figure 1B, 19c), by Mus-
limovic et al. (2007) on patients with and without dopaminergic
medication (Figure 1B, 14d), and by Pavão et al. (unpublished),
on patients tested without the effects of dopaminergic medication
(Figure 1B, identification code 15c; see Table S1 in Supplementary
Material).
COGNITIVE AND MOTOR IMPAIRMENTS
Figure 1C expresses a rapid progression of cognitive impairments
associated with a much slower progression of motor impairments
at earlier stages of the disease, followed by acceleration of motor
impairments at later stages of the disease associated with the cogni-
tive function already deteriorated. As seen above, while dopamin-
ergic medication reduces motor impairments associated with the
disease progression, it slightly increases cognitive impairments.
Muslimovic et al. (2007) showed that PD patients exhib-
ited cognitive impairments in absence of motor impairments
(Figure 1C, identification codes 14c and 14h; see Table S1 in
Supplementary Material) when tested at early stages of the dis-
ease without the effects of dopaminergic medication. However,
the combined analysis of their performances and the perfor-
mances observed in patients at advanced stages of the disease tested
under the effects of dopaminergic medication showed substantial
cognitive and motor impairments (Figure 1C, 14b and 14g).
In addition, significant correlations between cognitive and
motor impairments were found in early to advanced (Fama and
Sullivan, 2002; Vandenbossche et al., 2009; Verbaan et al., 2007)
and advanced PD patients (Caviness et al., 2007) tested under
the effects of dopaminergic medication (Figure 1C, identifica-
tion codes, 6a, 19b, 20a, and 1). Similarly, significant corre-
lations between cognitive and motor impairments were found
in patients tested without the effects of dopaminergic medica-
tion (identification code 15b; Pavão et al., unpublished) and
pooled early to advanced patients with and without dopamin-
ergic medication [identification code 13; Mortimer et al., 1982).
Less consistent correlation between cognitive and motor impair-
ments in patients at early stages of the disease tested with-
out the effects of dopaminergic medication were reported
by Cooper et al. (1991), which showed both significant and
non-significant correlations (Figure 1C, identification codes 3a
and 3b), likely related to the characteristics of the employed
tasks.
The remaining comparisons involving medicated PD, non-
medicated PD and control subjects, and the medication effects
in healthy subjects indicated in Figure 1C (identification codes 2a,
3c, 3d, 4, 6b, 6c, 8, 9b, 9d, 10a, 10b, 11, 12, 16, 18, 20b, and 21b)
were already analyzed above.
DISRUPTION OF IMPLICIT KNOWLEDGE ACQUISITION, MOTOR
IMPAIRMENT AND COGNITIVE IMPAIRMENTS, AND THE EFFECTS OF
DOPAMINERGIC MEDICATION
Figure 1D represents a unified model expressing the interac-
tion between disruption of implicit knowledge acquisition, motor
impairments, and general cognitive impairments, in patients at
early to advanced stages of the disease, tested both with and with-
out the effects of dopaminergic medication, along the disease pro-
gression. As shown, the progression of PD manifestations follows
different time courses, and dopaminergic medication has different
effects on each of these functions according to disease stages.
DISCUSSION
Assuming that progressions of motor impairments, disruption
of implicit knowledge acquisition, and cognitive impairments in
PD follow non-linear relationships (Figure 1), the present model
provides an explanation for the apparent conflict of data from dif-
ferent laboratories and for the effects of dopaminergic medication
on these manifestations (see Cooper et al., 1991; Muslimovic et al.,
2007; Vandenbossche et al., 2009; Pavão et al., unpublished).
Shortly, general cognitive impairments seem to be pronounced
at early stages of PD reaching a plateau when disruption of implicit
knowledge acquisition, paralleled by motor impairments, are still
in progression (Cooper et al., 1991; Fama and Sullivan, 2002;
Fern-Pollak et al., 2004; Deroost et al., 2006; Muslimovic et al.,
2007; Vandenbossche et al., 2009). Additionally, at any stage of PD,
dopaminergic medication seems to promote a substantial reduc-
tion of motor impairments, associated with increased disruption
of implicit knowledge acquisition (Swainson et al., 2000; Fern-
Pollak et al., 2004; Jahanshahi et al., 2010; Kwak et al., 2010; Seo
et al., 2010; Domellöf et al., 2011), and a subtle, if any, further
impairment of cognition (Press et al., 2002; Feigin et al., 2003;
Fern-Pollak et al., 2004; Morrison et al., 2004).
In addition to explaining the apparent conflict of data from
different laboratories, this model may be extended. For instance,
development of depression, a relevant aspect of the PD that cor-
relates with motor impairments (Cooper et al., 1991), has not
been considered here, and could also give rise to apparent con-
flicting results. An interesting challenge would be to integrate this
model with those advanced by Cools (2006) and Rowe et al. (2008)
distinguishing executive functions differentially affected by PD.
Independently on these possible future steps, the present model
seems to be useful for understanding the multifaceted progression
of PD and has testable predictive value regarding the progression of
PD manifestations as influenced or not on dopaminergic therapy.
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SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: http://www.frontiersin.org/Integrative_Neuroscience/10.3389/
fnint.2012.00056/abstract
Table S1 |The major findings of multiple studies were classified into three
functional domains, including motor, implicit knowledge acquisition and
general cognitive functions. The disease stage at which the patients were
tested, presence of dopaminergic medication effects on test results, tasks
employed, major results observed and correlation analysis with other functional
dimensions (when evaluated) were also included.
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